![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 2
2022
Eyre, Toby A.; Shah, Nirav N.; Dreyling, Martin; Jurczak, Wojciech; Wang, Yucai; Cheah, Chan Y.; Song, Yuqin; Gandhi, Mitul; Chay, Christopher; Sharman, Jeff; Andorsky, David J.; Messersmith, Hannah M.; Ruppert, Amy S.; Muthig, Valerie A.; Ito, Rodrigo und Wang, Michael L.
(2022):
BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma.
In: Future Oncology, Bd. 18, Nr. 36: S. 3961-3969
2019
Morschhauser, Franck; Flinn, Ian W.; Advani, Ranjana; Sehn, Laurie H.; Diefenbach, Catherine; Kolibaba, Kathryn; Press, Oliver W.; Salles, Gilles; Tilly, Herve; Chen, Andy I.; Assouline, Sarit; Cheson, Bruce D.; Dreyling, Martin; Hagenbeek, Anton; Zinzani, Pier Luigi; Jones, Surai; Cheng, Ji; Lu, Dan; Penuel, Elicia; Hirata, Jamie; Wenger, Michael; Chu, Yu-Waye und Sharman, Jeff
(2019):
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
In: Lancet Haematology, Bd. 6, Nr. 5, E254-E265